CN1543337A - 可膨胀的胃潴留装置 - Google Patents

可膨胀的胃潴留装置 Download PDF

Info

Publication number
CN1543337A
CN1543337A CNA018235441A CN01823544A CN1543337A CN 1543337 A CN1543337 A CN 1543337A CN A018235441 A CNA018235441 A CN A018235441A CN 01823544 A CN01823544 A CN 01823544A CN 1543337 A CN1543337 A CN 1543337A
Authority
CN
China
Prior art keywords
agent
retention device
gastric retention
gastric
grd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018235441A
Other languages
English (en)
Chinese (zh)
Inventor
ղķʿ��W������˹
詹姆士·W·埃里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of CN1543337A publication Critical patent/CN1543337A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0409Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0409Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414Particles, beads, capsules or spheres
    • A61K49/0419Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CNA018235441A 2001-08-16 2001-10-22 可膨胀的胃潴留装置 Pending CN1543337A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
US60/313,078 2001-08-16

Publications (1)

Publication Number Publication Date
CN1543337A true CN1543337A (zh) 2004-11-03

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018235441A Pending CN1543337A (zh) 2001-08-16 2001-10-22 可膨胀的胃潴留装置

Country Status (14)

Country Link
EP (1) EP1416914A1 (fr)
JP (1) JP2005501097A (fr)
KR (1) KR20040032918A (fr)
CN (1) CN1543337A (fr)
BR (1) BR0117123A (fr)
CA (1) CA2456976A1 (fr)
CO (1) CO5670360A2 (fr)
IL (1) IL160363A0 (fr)
MX (1) MXPA04001388A (fr)
NO (1) NO20040611L (fr)
NZ (1) NZ531461A (fr)
PL (1) PL368327A1 (fr)
WO (1) WO2003015745A1 (fr)
ZA (1) ZA200402066B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552103A (zh) * 2010-12-20 2012-07-11 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
CN112004520A (zh) * 2017-12-18 2020-11-27 特瑞斯制药公司 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214314A (pt) * 2001-11-21 2004-11-09 E Z Em Inc Formulações para uso em procedimentos médicos ou de diagnóstico
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
JP2009543886A (ja) * 2006-07-19 2009-12-10 スミスクライン・ビーチャム・コーポレイション ガンマシンチグラフィー評価のために処方物を放射性標識する方法
EP2858604B1 (fr) 2012-06-07 2024-02-21 Epitomee Medical Ltd Dispositif étendu
EP3091962B1 (fr) 2013-12-05 2022-06-08 Epitomee Medical Ltd. Dispositifs et systèmes de rétention pour la libération in-situ d'agents pharmaceutiques actifs
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
EP3155024B1 (fr) 2014-06-11 2020-09-16 Massachusetts Institute Of Technology Structures rétentifs et procédés associés
JP2018515476A (ja) 2015-05-01 2018-06-14 マサチューセッツ インスティテュート オブ テクノロジー 誘発性形状記憶誘導デバイス
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US11992552B2 (en) 2015-12-08 2024-05-28 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
CN110022861B (zh) 2016-09-30 2024-06-28 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
US12023406B2 (en) 2017-06-09 2024-07-02 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
TR201914116A2 (tr) * 2019-09-17 2021-04-21 Univ Yeditepe Doğal bi̇yomateryaller i̇le kri̇yojelleri̇n üreti̇m yöntemi̇ ve bu kri̇yojelleri̇n yumuşak doku i̇skelesi̇ veya i̇laç taşiyici si̇stem olarak kullanimi
WO2022195476A1 (fr) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
WO1999007342A1 (fr) * 1997-08-11 1999-02-18 Alza Corporation Forme galenique d'un agent actif a liberation prolongee adaptee a la retention gastrique
EE200100153A (et) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Kontrollitav ravimiväljutussüsteem ravimite suukaudseks manustamiseks, mis pakub ajalist ja ruumilist kontrolli
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
EA200300046A1 (ru) * 2000-06-23 2003-10-30 Тева Фармасьютикал Индастриес Лтд. Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552103A (zh) * 2010-12-20 2012-07-11 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
CN112004520A (zh) * 2017-12-18 2020-11-27 特瑞斯制药公司 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物

Also Published As

Publication number Publication date
CA2456976A1 (fr) 2003-02-27
NZ531461A (en) 2008-03-28
PL368327A1 (en) 2005-03-21
MXPA04001388A (es) 2004-05-27
IL160363A0 (en) 2004-07-25
NO20040611L (no) 2004-04-16
EP1416914A1 (fr) 2004-05-12
WO2003015745A1 (fr) 2003-02-27
BR0117123A (pt) 2004-09-28
JP2005501097A (ja) 2005-01-13
ZA200402066B (en) 2005-05-09
CO5670360A2 (es) 2006-08-31
KR20040032918A (ko) 2004-04-17

Similar Documents

Publication Publication Date Title
CN1543337A (zh) 可膨胀的胃潴留装置
KR100618234B1 (ko) 다공성 입자를 포함하는 제형
EP0205336B1 (fr) Préparation pharmaceutique orale à effet entretenn
JP5607550B2 (ja) 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
US20040219186A1 (en) Expandable gastric retention device
CN1096862C (zh) 阿齐霉素的控释剂型
JP3403203B2 (ja) ダリフェナシン含有製剤
CN1402632A (zh) 水凝胶驱动的药物剂型
JP2004514732A (ja) 迅速に分散する医薬組成物
CN1489455A (zh) 延释药物制剂
MXPA02004413A (es) Induccion farmacologica del modo de alimentacion, para la administracion aumentada de drogas al estomago.
JP2008510000A (ja) 制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
CN1461212A (zh) 水凝胶驱动的药物剂型
CN1688291A (zh) 含有固体药物分散体的即刻释放剂型
TWI415633B (zh) Solid preparations containing enteric solid dispersions
US20150150867A1 (en) Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
TW200819128A (en) Extended release gastro-retentive oral drug delivery system for valsartan
CN1289069C (zh) 含有5ht1受体激动剂的药物组合物
CN87104918A (zh) 可控释放的含药物纤维
CN1151783C (zh) 舍曲林的缓释剂型
WO2007010847A1 (fr) Préparation à libération prolongée
Bhosale et al. A comprehensive review on floating drug delivery system (FDDS)
US6555135B1 (en) Pharmaceutical compositions comprising co-micronized fenofibrate
CN104853752B (zh) 嘧啶二酮衍生物化合物的制剂
HU229569B1 (hu) Szelektív szerotoninújrafelvétel-gátlók szabályozott kibocsátású többrészecskés kiszerelései

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1067056

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1067056

Country of ref document: HK